Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda symbols : Aqst save search
Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
Published: 2024-03-14 (Crawled : 21:00) - globenewswire.com
AQST | $4.265 -2.63% -2.7% 1.7M
|
Health Technology
|
| O: 3.05%
H: 14.23%
C: 12.57%
fda update meeting therapeutics study
Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date
Published: 2023-09-11 (Crawled : 12:00) - globenewswire.com
AQST | $4.265 -2.63% -2.7% 1.7M
|
Health Technology
|
| O: -0.67%
H: 11.41%
C: 5.37%
fda drug application therapeutics
Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)
Published: 2023-04-20 (Crawled : 12:20) - aquestive.com
AQST | $4.265 -2.63% -2.7% 1.7M
|
Health Technology
|
| O: 1.45%
H: 2.86%
C: -1.43%
aqst-109 fda candidate therapeutics
Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)
Published: 2022-12-22 (Crawled : 13:20) - aquestive.com
AQST | $4.265 -2.63% -2.7% 1.7M
|
Health Technology
|
| O: -0.38%
H: 5.5%
C: 0.22%
aqst-109 fda meeting therapeutics phase 2
Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film
Published: 2022-10-11 (Crawled : 12:20) - aquestive.com
AQST | $4.265 -2.63% -2.7% 1.7M
|
Health Technology
|
| O: 1.96%
H: 8.65%
C: 3.85%
aqst-109 fda therapeutics response epinephrine positive
Aquestive Therapeutics Receives FDA Tentative Approval for Libervant™ (diazepam) Buccal Film
Published: 2022-08-31 (Crawled : 12:20) - aquestive.com
AQST | $4.265 -2.63% -2.7% 1.7M
|
Health Technology
|
| O: -6.58%
H: 3.52%
C: 1.76%
fda tentative approval therapeutics
Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-109 for Emergency Treatment of Allergic Reactions Including Anaphylaxis
Published: 2022-03-17 (Crawled : 13:00) - biospace.com/
AQST | $4.265 -2.63% -2.7% 1.7M
|
Health Technology
|
| O: 8.57%
H: 4.1%
C: 1.63%
aqst-109 fast track designation react treatment fda fast track therapeutics fda fast track merge designation
Aquestive Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for AQST-109 Epinephrine Oral Film
Published: 2022-02-25 (Crawled : 03:00) - globenewswire.com
AQST | $4.265 -2.63% -2.7% 1.7M
|
Health Technology
|
| O: 7.66%
H: 0.0%
C: 0.0%
aqst-109 new drug fda clearance application drug therapeutics fda clearance epinephrine
Aquestive Therapeutics Receives Notification from FDA that It Will Not Be Ready to Take Action by December 23, 2021 for the Company’s NDA for Libervant™ (diazepam) Buccal Film
Published: 2021-12-21 (Crawled : 06:00) - globenewswire.com
AQST | $4.265 -2.63% -2.7% 1.7M
|
Health Technology
|
| O: -30.71%
H: 8.58%
C: 2.09%
fda therapeutics
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application (NDA) Resubmission for Libervant™ (diazepam) Buccal Film
Published: 2021-07-19 (Crawled : 14:00) - globenewswire.com
AQST | $4.265 -2.63% -2.7% 1.7M
|
Health Technology
|
| O: 3.61%
H: 6.98%
C: 4.07%
new drug fda fda acceptance drug submission application resubmission
Aquestive Therapeutics Reaffirms Near-Term NDA Resubmission for Libervant™ (diazepam) Buccal Film Following FDA Feedback
Published: 2021-02-25 (Crawled : 13:00) - globenewswire.com
AQST | $4.265 -2.63% -2.7% 1.7M
|
Health Technology
|
| O: -1.0%
H: 1.29%
C: -7.18%
fda submission resubmission
Aquestive Therapeutics Advances Royalty Monetization Plan as Sunovion Pharmaceuticals’ Apomorphine Sublingual Film Therapy Receives FDA Approval
Published: 2020-05-21 (Crawled : 09:08) - globenewswire.com
AQST | $4.265 -2.63% -2.7% 1.7M
|
Health Technology
|
| O: 6.18%
H: 2.6%
C: -11.94%
therapy fda approval fda approval
Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Treatment of Allergic Reactions Including Anaphylaxis
Published: 2020-08-10 (Crawled : 09:08) - globenewswire.com
AQST | $4.265 -2.63% -2.7% 1.7M
|
Health Technology
|
| O: 2.23%
H: 10.58%
C: 8.09%
fda liver treatment fast track fda fast track fast track designation designation
Aquestive Therapeutics Receives Complete Response Letter from FDA for Libervant™ (diazepam) Buccal Film for Management of Seizure Clusters
Published: 2020-09-25 (Crawled : 09:08) - globenewswire.com
AQST | $4.265 -2.63% -2.7% 1.7M
|
Health Technology
| Email alert
Add to watchlist
fda response
Aquestive Therapeutics Completes FDA Type A Meeting on Libervant
Published: 2020-11-18 (Crawled : 09:08) - globenewswire.com
AQST | $4.265 -2.63% -2.7% 1.7M
|
Health Technology
|
| O: 3.67%
H: 13.85%
C: 10.92%
fda therapeutics
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.